CELLBANKER® freezing media from AMSBIO is now available in customizable formats, seamlessly integrating into cell manufacturing processes with personalized formulations, volumes, and packaging.
Cited in over 500 scientific publications, the CELLBANKER range has proven itself as a safe and reliable solution for storing cells and tissues. This includes GMP-grade, chemically defined formulations specifically designed for the storage of biospecimens for clinical applications.
Widespread adoption of cell and gene therapies has required new advances in cell manufacturing and processing to produce…
• Sentiment among UK CFOs has risen for the second consecutive quarter, with optimism running well above average levels;
• Inflation and high interest rates have dropped down the CFO risk list;1
• Corporate risk appetite has risen to an 18-month high but remains subdued relative to its long-term average;
• 63% of CFOs anticipate higher investment in new technology;
• CFOs believe geopolitical factors pose the greatest external risk to their own businesses over the next 12 months.
CFOs of the UK’s largest firms are optimistic about prospects for their own businesses as they enter 2024,…
CAMBRIDGE, UK & BOSTON, US – JANUARY 2, 2024 – Apollo Therapeutics (“Apollo” or “the Company”), a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines through a hub-and-spoke approach, today announces that during December 2023 it completed a second close of its Series C financing, raising an additional $33.5 million and bringing the total raised in this round by the Company during 2023 to $260 million.
“We are delighted to have completed the second close of our Series C financing in December and thank existing investors for their…
ARECOR ANNOUNCES EXPANSION OF EXISTING SPECIALTY HOSPITAL FORMULATION COLLABORATION
Cambridge, UK, 8 January 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces the expansion of its ongoing, exclusive formulation study collaboration with the pharmaceutical division of one of the world’s largest chemicals marketing and pharmaceuticals companies, which focuses on the development and commercialisation of speciality drugs.
The collaboration, in which Arecor is using its proprietary formulation technology…
Helix Geospace, a leading developer of next-generation antennas and systems, has leased laboratory space at Abingdon Science Park: one of the UK’s critical science and technology hubs.
Owned and developed by Kadans Science Partner, the brand new, laboratory accommodation is designed to meet the demands of innovative occupiers.
London, 8 January, 2024 – Helix Geospace has become the latest business to make Abingdon Science Park its new home, leasing brand new, best-in-class laboratory accommodation in Sovereign House, joining the vibrant community of knowledge intensive…
Happy new year to our fantastic members, partners, sponsors and collaborators. To help you prep for this year, see our January eNews: Leap into Your Life Science Opportunities in 2024, featuring:✅ Welcome from Tony Jones, CEO, One Nucleus✅ Boston Bootcamp✅ Building Life Science Adventures (BLSA) 2024✅ BIO-Europe Spring 2024✅ Our Inaugural Annual Awards Dinner✅ ON Helix 2024✅ Develop Yourself in 2024!✅ Make the Most of Your Corporate Membership
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR APPOINTS DR HELEN PARRIS AS SENIOR VICE PRESIDENT, COMMERCIAL AND GENERAL MANAGER OF TETRIS PHARMA LTD
Cambridge, UK, 3 January 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, is pleased to announce the appointment of Dr. Helen Parris as Senior Vice President, Commercial and General Manager of the Group’s subsidiary company, Tetris Pharma Ltd ("Tetris Pharma”), effective Monday 15 January 2024.
Helen has over 20 years of scientific, commercial and…
James Sheppard, Managing Director (UK&I) at Kadans
Maintaining the pace of innovation required during the pandemic was never going to be easy. From the boom in demand in 2020, to the inflationary and market pressures in 2023, it has been a turbulent few years for the life sciences industry.
As companies continue to adapt to soaring energy bills, tighter budgets, and a new way of working, they are still expected to keep pace with innovation and deliver outstanding results for the industry. In turn, demand for specialised office and laboratory facilities is soaring to satisfy these needs,…
VANCOUVER, Wash., US and OXFORD, UK, December 20, 2023 — Absci (Nasdaq: ABSI), a generative AI drug creation company, and PrecisionLife®, a leading computational biology company driving precision medicine in complex chronic diseases, today announced a collaboration to develop a joint portfolio of potential therapeutics addressing unmet medical needs. The collaboration combines Absci’s speed and strength in antibody design and optimization with PrecisionLife’s deep understanding of complex disease biology and expertise in identifying the mechanisms, drug targets and treatments that are…
Financing led by Maven Capital Partners, alongside Gresham House Ventures
Funds to be used to expand Metrion’s Cambridge UK laboratories and to enhance scientific and commercial capabilities
Dr David Milroy and Steve Carle appointed to the board
Cambridge, UK, 20 December 2023: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced that it has secured £3.5m in new equity financing, including £2.5m from lead investor Maven Capital Partners (Maven) and £1 million from existing investor, Gresham House Ventures (Gresham…